One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
BioLineRx Ltd.
BLRX · NCM · Healthcare · Biotechnology
Current price
$1.71
52-week range
$1.70 - $3.95
Market cap
$8.51M
Balance sheet
Healthy
-8.22x Concerning
Net cash $5.14M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
BioLineRx Ltd.
BioLineRx Ltd. is a drug company that creates new medicines for cancer and rare illnesses. Their main money comes from selling these medicines, and it matters because it shows how well their treatments are working and if they can keep developing new ones.
How the company got here
BioLineRx Ltd. was founded in 2003 as a joint venture involving several entities, including Teva Pharmaceutical Industries and the Jerusalem Development Authority. The company went public on the Tel Aviv Stock Exchange in 2007 and later began trading its American Depositary Receipts (ADRs) on the NASDAQ Capital Market in 2011. Initially, BioLineRx focused on in-licensing promising drug candidates, primarily from Israeli institutions, and advancing them through clinical trials before partnering with larger pharmaceutical companies for further development and commercialization. A significant turning point was the U.S. Food and Drug Administration (FDA) approval of its first product, APHEXDA (motixafortide), in September 2023, marking its transition to a commercial-stage company.
What it actually does
BioLineRx is a biopharmaceutical company that focuses on developing and commercializing treatments for cancer and rare diseases. They identify potential new medicines, often from academic research or smaller biotech firms, and then guide these drug candidates through the complex process of clinical testing. The ultimate goal is to bring these potential therapies to patients who need them, either by developing them themselves or by partnering with larger pharmaceutical companies.
APHEXDA (motixafortide)
APHEXDA, also known by its scientific name motixafortide, is BioLineRx's first approved product. It is used in the United States to help mobilize stem cells for patients undergoing autologous transplantation, a procedure often used in treating multiple myeloma, a type of blood cancer. This means APHEXDA helps the body produce and release more stem cells into the bloodstream, which can then be collected and used in the transplant. The company has partnered with other firms, like Ayrmid Ltd. and Gloria Biosciences, to commercialize APHEXDA in different regions of the world.
GLIX1
GLIX1 is an investigational drug that BioLineRx is developing as a potential treatment for certain types of cancer, particularly glioblastoma (a type of brain cancer) and other solid tumors. It works by targeting the DNA damage response within cancer cells, aiming to selectively kill cancer cells while sparing healthy ones. BioLineRx is collaborating with Hemispherian AS to advance GLIX1 through clinical trials, with early-stage studies focusing on determining the optimal dosage and evaluating its safety and effectiveness.
BL-5010
BL-5010 is an older, or legacy, product in BioLineRx's portfolio. It is designed for the non-surgical removal of skin lesions, delivered through a pen-like applicator containing an acidic solution. While not a primary focus of current development, it represents a different area of therapeutic application compared to their main oncology and rare disease pipeline.
What management is betting on now
BioLineRx's current strategy centers on advancing its pipeline of innovative therapies, particularly APHEXDA and GLIX1, through clinical development and commercialization. Following the FDA approval of APHEXDA, the company has shifted towards a model that emphasizes royalties and milestones from out-licensing agreements, aiming to reduce operational costs. Management is focused on exploring new indications for APHEXDA and advancing GLIX1 in various cancer types, often through strategic collaborations with academic institutions and other pharmaceutical companies.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $1.71
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $5.1M - more cash than debt. Interest coverage -8.2x.
Net debt
$-5.14M
Interest coverage
-8.22x
BioLineRx Ltd. is healthier than 0 of 1 peers on balance-sheet leverage.
Healthy
Worse cushion
Baseline
Better cushion
BLRX
BASELINE
BioLineRx Ltd.
Total debt $7.94M Interest coverage -8.22x This is the baseline the peer rows are being compared against.
What you should know
The case for and against BLRX
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -55.3% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.68x
P/B
0.57x
P/S
6.12x
EV/EBITDA
-0.45x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
80.0%
Operating margin
-1,215.3%
Net margin
0.0%
ROE
-55.3%
ROA
-19.8%
Health
Liquidity and balance-sheet strength
Debt / equity
0.48x
Current ratio
1.20x
Quick ratio
1.01x
Total debt
$7.94M
Total cash
$13.08M
Growth
How the business has been compounding
Revenue TTM
$1.39M
Revenue 5Y CAGR
—
EPS TTM
0.00
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-8.07M
Free CF TTM
$-8.10M
FCF margin
-582.0%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—